New cash-paying patients can now access Wegovy/Ozempic for $199 a month. Here's what that means for Novo Nordisk stock.

Novo Nordisk offers limited-time $199 pricing on Wegovy and Ozempic, lowers self-pay costs, and prepares for a stronger Wegovy pill rollout.

This prompted an unusual and bitter bidding war, where Doustdar goaded Pfizer to raise its bid during a press conference in the Oval Office. In the end, Pfizer won by matching Novo’s $10bn offer, as the Federal Trade Commission intervened to raise concerns about the potential merger.

The Danish anti-obesity drugmaker slashed prices for its Wegovy and Ozempic treatments. Shares fell more than 1%. ↘️ [XPeng (HK:9868](

Novo Holdings, which controls obesity drugmaker Novo Nordisk, will sell 154.5 million shares, or 7.8% of its stake, in British medical products maker ConvaTec Group, a bookrunner for the offering said on Monday.

Novo Nordisk's new chair Lars Sorensen plans to add pharma expertise and address governance concerns after a major board overhaul backed by the company's foundation.

Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, capping a whirlwind two weeks in which rival pharma Novo Nordisk attempted to swoop in and snatch the startup from under Pfizer’s nose.

Wegovy-maker Novo Nordisk's CEO said on Monday a deal with the White House to slash prices on its popular weight‑loss drugs aimed to broaden access to the U.S. Medicare programme, a federal health insurance programme for people aged 65 and older or who have disabilities.